報價延遲最少15分鐘:2026/04/15 22:31 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
25.85 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
1.68/2.91
|
|
企業價值
3.20B
|
| 資產負債 |
|
每股賬面淨值
7.81
|
| 現金流量 |
|
現金流量率
0.06
|
| 損益表 |
|
收益
491.73M
|
|
每股收益
2.85
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept. |
